Physician profile
Mark Scott True
NPI 1902881261
$3,608.44
in general payments reported to CMS, 2019-2025
13 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $341 · 2021: $239 · 2022: $115 · 2023: $239 · 2024: $323 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conformis, INC. | $1,256.85 | 2019-2022 | |
| Pacira Therapeutics, INC. | $642.53 | 2019-2020 | |
| Smith+Nephew, INC. | $638.77 | 2019-2023 | Or3o Dual Mobility, Ri Hip Navigation |
| Stryker Corporation | $476.27 | 2019-2025 | Mako, Insignia |
| Depuy Synthes Sales INC. | $299.24 | 2024-2025 | Orthovisc, Monovisc, Actis |
| Spr Therapeutics, INC | $117.07 | 2020 | |
| Angiodynamics, INC. | $42.09 | 2021 | |
| Boston Scientific Corporation | $35.26 | 2023 | Wavewriter Alpha Prime 16 |
| Zimmer Biomet Holdings, INC. | $26.92 | 2019 | |
| Bioventus LLC | $23.35 | 2024 | Durolane |
| Nevro Corp. | $22.80 | 2022 | |
| Medical Device Business Services, INC. | $13.67 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $13.62 | 2024 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark True listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.